News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The product will be launched in Q1FY26
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Subscribe To Our Newsletter & Stay Updated
